PDF(Pubmed)
Abstract：
Photoimmunotherapy (PIT) targets and destroys tumor cells through irradiation with 690-nm red light after the administration of cetuximab sarotalocan sodium, which contains IRDye700DX bound to cetuximab. In Japan, PIT is a new treatment that is covered by insurance only for unresectable head and neck cancers. However, this treatment has conditional early approval. There have been no case reports describing the efficacy of this treatment in a real-world setting thus far. We report our experience with PIT for head and neck cancer. A 76-year-old man with laryngeal cancer underwent radiation therapy and surgery. Skin involvement in the right submandibular region was subsequently noted. We diagnosed local recurrence and performed PIT for this lesion. Partial response was achieved after the first PIT session, and progressive disease was diagnosed after the second session. Many aspects of PIT remain unclear and should, therefore, be clarified in further research. Despite this uncertainty, PIT may become an effective treatment strategy for head and neck cancer if the patient selection criteria are delineated.
摘要：
光免疫疗法（PIT）在服用西妥昔单抗沙罗通钠后，通过690nm红光照射靶向并破坏肿瘤细胞，其中含有与西妥昔单抗结合的IRDye700DX。在日本,PIT是一种新疗法，仅适用于不可切除的头颈部癌症。然而,这种治疗有条件的早期批准。到目前为止，还没有病例报告描述这种治疗在现实世界中的疗效。我们报告了我们对头颈癌的PIT的经验。一名76岁的喉癌患者接受了放射治疗和手术。随后注意到右侧颌下区域的皮肤受累。我们诊断为局部复发，并对该病变进行了PIT。在第一次PIT会议之后获得了部分响应，在第二次会议后诊断出进行性疾病。PIT的许多方面仍然不清楚，应该，因此,在进一步的研究中得到澄清。尽管存在这种不确定性,如果描述了患者选择标准，PIT可能成为头颈癌的有效治疗策略。
